HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

RDY

Dr. Reddy's Laboratories Limited (NYSE)

Healthcare — Drug Manufacturers - Specialty & Generic

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Hold 2.6 / 5 5 analysts
$13.99
$-0.50 (-3.45%)
Target: $14.12 (0.9%)
Sign in to add RDY to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$11.65B
P/E Ratio (TTM)25.44
Forward P/E20.97
EPS (TTM)$0.55
Dividend Yield0.60%
Profit Margin12.76%
Revenue Growth-11.60%
ROE11.83%
Debt/Equity20.33
Recommendation Hold 2.6
Analyst Target$14.12
Analysts5
Indexes NYSE

Technical Indicators

RSI (14)58.7
Beta0.26
SMA 20-
SMA 40-
52-Week High$15.67
52-Week Low$12.19
50-Day Avg$13.58
200-Day Avg$13.86
Avg Volume$2.56M
Volume$3.00M

Performance Analysis

BULLISH

RDY shows predominantly bullish signals based on its fundamentals and technicals.

~ Trading at 52% of its 52-week range.
+ RSI at 58.7 shows positive momentum.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
- Revenue declined 11.6% year-over-year.
~ Wall Street consensus is "Hold" from 5 analysts.
+ Average analyst target of $14.12 implies 0.9% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:28 UTC

Back to Screener Export Report